Generalized pustular psoriasis (GPP) is a severe and potentially life-threatening type of psoriasis. We present the case of a patient with severe GPP, at first unsuccessfully treated with cyclosporine. We chose to treat the patient with ixekizumab, an anti-IL-17 antibody known for its rapid action in psoriasis vulgaris, that has also been reported as effective in GPP. The patient improved rapidly, with resolution of the active lesions after the first administration. The treatment has been continued for 2 years, with no adverse events and sustained disease control. Ixekizumab could be considered a safe and effective option in patients with GPP.
Severe Generalized Pustular Psoriasis Successfully Treated with Ixekizumab: A Case Report
Burlando, Martina;Salvi, Ilaria;Paravisi, Andrea;Cozzani, Emanuele;Parodi, Aurora
2022-01-01
Abstract
Generalized pustular psoriasis (GPP) is a severe and potentially life-threatening type of psoriasis. We present the case of a patient with severe GPP, at first unsuccessfully treated with cyclosporine. We chose to treat the patient with ixekizumab, an anti-IL-17 antibody known for its rapid action in psoriasis vulgaris, that has also been reported as effective in GPP. The patient improved rapidly, with resolution of the active lesions after the first administration. The treatment has been continued for 2 years, with no adverse events and sustained disease control. Ixekizumab could be considered a safe and effective option in patients with GPP.
| File | Dimensione | Formato | |
|---|---|---|---|
|
526037.pdf
accesso aperto
Tipologia:
Documento in versione editoriale
Dimensione
530.83 kB
Formato
Adobe PDF
|
530.83 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
